Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Monoclonal Antibody May Benefit Patients With Kidn

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153802
(Total Views: 530)
Posted On: 05/29/2024 1:56:56 PM
Posted By: Enjay
Monoclonal Antibody May Benefit Patients With Kidney Transplant Rejection

An investigational monoclonal antibody appeared to have therapeutic benefits among kidney transplant patients with antibody-mediated rejection, a randomized phase II trial showed.

After 24 weeks, resolution of morphologic antibody-mediated rejection occurred in nine of the 11 participants who received infusions of the CD38 monoclonal antibody felzartamab compared with two of 10 placebo-treated participants, reported Georg Böhmig, MD, of the Medical University of Vienna, and colleagues in the New England Journal of Medicine.

Originally developed for multiple myeloma, felzartamab is a fully human IgG1 monoclonal CD38 antibody that depletes target cells through antibody-dependent cellular cytotoxicity and phagocytosis.

https://www.medpagetoday.com/nephrology/kidne...ate_active




Ohm's list includes chronic kidney disease (due to inflammation). After Leronlimab is available for kidney disease, there will hopefully be fewer kidney transplants. Where transplants are necessary, Leronlimab may be needed on a long-term basis. The article included the following comment:

Quote:
However, treatment effects were not durable after discontinuation, with three of nine patients responsive to felzartamab having a recurrence of antibody-mediated rejection by week 52, along with an increase in molecular activity and biomarker levels toward baseline levels.



Discussion of week 52 means this requires a very long study. When the buyout ultimately comes, I look forward to seeing various posters' thoughts on buying shares in whoever does the buyout. I suspect ohm would say that research will develop many more possibilities than his list of 90. Many of those, however, will require long trials.

I don't want to jinx a buyout, but one would think that purchasing stock in the buyer would be a good long-term investment.


(5)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us